Serotonin reuptake inhibitor

Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration

Retrieved on: 
목요일, 11월 23, 2023
Safety, Food, ODD, US Food Sovereignty Alliance, IND, Patient, FDA, Partnership, Drug development, RET, Orphan, Serotonin reuptake inhibitor, AACR, Pharmaceutical industry, SRI, Ellipses

LONDON, Nov. 23, 2023 /PRNewswire/ -- Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announces today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its compound, EP0031/A400, a potential treatment for tissue-agnostic RET fusion-positive solid tumours.

Key Points: 
  • LONDON, Nov. 23, 2023 /PRNewswire/ -- Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announces today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its compound, EP0031/A400, a potential treatment for tissue-agnostic RET fusion-positive solid tumours.
  • The FDA grants ODD for investigational treatments for rare diseases, such as RET fusion-positive solid tumours, defined as affecting fewer than 200,000 people in the United States.
  • ODD qualifies the developer for certain incentives with the goal of accelerating drug development for patients, including tax credits and seven years of market exclusivity in the US upon approval by the FDA.
  • [1]
    It is estimated that RET mutations and rearrangements may be responsible for ~2% of all solid tumours.

Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor

Retrieved on: 
수요일, 12월 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Monroe Dunaway Anderson, MTC, Drug, NMPA, IND, UCLA, Partnership, Medullary thyroid cancer, Patient, RET, Cancer, NSCLC, Thyroid, Serotonin reuptake inhibitor, CMO, SRI, Clinical trial, University, Safety, University of Kentucky, Neoplasm, Pharmaceutical industry, EU, Ellipses

Ellipses Pharma (Ellipses), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of a patient in EP0031-101, a trial investigating Ellipses next generation selective RET inhibitor (SRI) EP0031.

Key Points: 
  • Ellipses Pharma (Ellipses), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of a patient in EP0031-101, a trial investigating Ellipses next generation selective RET inhibitor (SRI) EP0031.
  • Next generation SRIs offer the potential to expand the armamentarium against RET-driven cancers and further improve patient outcomes.
  • We are pleased that the EP0031-101 trial has dosed the first patient in the United States and congratulate our partner Ellipses on this important milestone.
  • EP0031 is a potent next generation SRI with broad activity against common RET fusions and mutations, including solvent front resistance mutations.

Manzil Launches Manzil Invest, Canada's First Actively Managed Halal Digital Investment Platform

Retrieved on: 
수요일, 10월 26, 2022
Islamic banking and finance, CIIS, Islam, Goal, Serotonin reuptake inhibitor, Firearm, CEO, Onevest, IIROC, The Children's Investment Fund Management, Tobacco, Compliance, Investment Industry Regulatory Organization of Canada, Adult, GLOBE, Investment, Knowledge, Canadian Investor Protection Fund, Cryptocurrency, Financial services, Bank, Financial adviser

TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Toronto-based Manzil , a tech-enabled ethical neo-financial services platform, announced today that it has launched Manzil Invest powered by OneVest Management Inc. ( OneVest ), Canada's first actively managed Halal digital investment platform.

Key Points: 
  • TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Toronto-based Manzil , a tech-enabled ethical neo-financial services platform, announced today that it has launched Manzil Invest powered by OneVest Management Inc. ( OneVest ), Canada's first actively managed Halal digital investment platform.
  • The launching of Manzil Invest is a significant milestone for Canadian Muslims who seek to adhere to their religious values.
  • Currently, access to professionally managed Halal portfolio options through a bank, brokerage or specialty portfolio management shops comes with a significant investment minimum, anywhere from $100K - $500K.
  • Manzil is a privately-held Canadian company and the only Canadian Islamic Neo-financial services platform that manufactures and distributes Halal financial solutions, including home financing and investment funds.

Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-altered Malignancies

Retrieved on: 
수요일, 6월 22, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, NDA, Drug development, Safety, NMPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Investigational New Drug, Control, Clinical trial, Serotonin reuptake inhibitor, IND, Partnership, Food, Chemistry, Patient, CMC, Autoimmunity, RET, SRI, Pharmaceutical industry, Fine chemical, Ellipses, EU

Kelun-Biotech has already commenced a clinical trial of EP0031 (A400) in China, which is progressing rapidly towards the dose expansion stage.

Key Points: 
  • Kelun-Biotech has already commenced a clinical trial of EP0031 (A400) in China, which is progressing rapidly towards the dose expansion stage.
  • Approval of the IND is a significant step in the initiation of a global, modular Phase 1/2 trial to evaluate the safety, tolerability and efficacy of EP0031 in patients with advanced RET-altered cancers including patients who have not received prior treatment with first generation SRIs.
  • EP0031 is a potent next generation SRI with broad activity against common RET fusions and mutations, including solvent front resistance mutations.
  • An IND application for EP0031 (A400) was approved by Chinas National Medicinal Products Administration (NMPA) in June 2021 and a Phase 1/2 trial is ongoing in China.

SRI International Enters Drug Discovery and Research Collaboration with Sanofi

Retrieved on: 
수요일, 7월 7, 2021
Companies, California, San Francisco Bay Area, SRI International, Menlo Park, California, Menlo, Sanofi, Serotonin reuptake inhibitor, SRI

MENLO PARK, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SRI International (SRI) today announced that the company has entered a research collaboration with Sanofi.

Key Points: 
  • MENLO PARK, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SRI International (SRI) today announced that the company has entered a research collaboration with Sanofi.
  • SRIs SynFini platform combines AI and automation to accelerate small molecule drug discovery and development, and thereby bring new drugs to the clinic more quickly and affordably.
  • Utilizing reasoning-guided deep neural networks, DASL efficiently predicts drug designs from the sparse data sets that are typically available in drug discovery.
  • SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education.

Millions to gain access to Psychedelic Psychotherapy in bid to fight pandemic induced depression and anxiety

Retrieved on: 
목요일, 6월 17, 2021
Psychoactive drugs, Selective serotonin reuptake inhibitors, Drugs, Antidepressants, Chemical compounds, Serotonin reuptake inhibitor, Fluoxetine, Citalopram, Escitalopram, Development and discovery of SSRI drugs, Management of depression

Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.

Key Points: 
  • Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.
  • One-in-ten Americans are taking anti-depressant medication with the majority taking selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Celexa and Lexapro.
  • However an increasing number of people believe anxiety and depression stems from internalised trauma which SSRIs fail to tackle.
  • The pandemic has exacerbated the mental health crisis, with some 100 million now estimated to be dealing with depression today.

Selective Serotonin Reuptake Inhibitors (SSRIs) Market- AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., among others to contribute to the market growth|Industry Analysis, Market Trends, Opportunities and Forecast 2025

Retrieved on: 
금요일, 4월 2, 2021
Selective serotonin reuptake inhibitors, Pharmacology, Branches of biology, Drugs, Serotonin reuptake inhibitor, Serotonin, Reuptake inhibitor, Serotonin–norepinephrine reuptake inhibitor, Allosteric serotonin reuptake inhibitor

The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.

Key Points: 
  • The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.
  • The report on the selective serotonin reuptake inhibitors (SSRIs) market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • This study identifies the growing geriatric population as one of the prime reasons driving the selective serotonin reuptake inhibitors (SSRIs) market growth during the next few years.
  • The selective serotonin reuptake inhibitors (SSRIs) market covers the following areas:

SRI International awarded $4.3M from DARPA to create rapid response therapeutic manufacturing system

Retrieved on: 
수요일, 10월 7, 2020
Contract research organizations, San Francisco Bay Area, California, SRI International, Serotonin reuptake inhibitor, Medical research, States of the United States

SRIs SynFini platform is a fully automated synthetic chemistry system that designs and synthesizes chemical molecules.

Key Points: 
  • SRIs SynFini platform is a fully automated synthetic chemistry system that designs and synthesizes chemical molecules.
  • ProSyn will rapidly translate processes developed on SynFini to desired production levels, providing just-in-time and scalable manufacturing capacity.
  • SRI previously received funding under DARPAs Make-It program that supported the development and evaluation of SynFini.
  • SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development.

SPRAVATO®▼ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder

Retrieved on: 
목요일, 12월 19, 2019
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Psychoactive drugs, Drugs, Antidepressants, Amines, Chloroarenes, Dopamine reuptake inhibitors, Esketamine, Serotonin–norepinephrine reuptake inhibitor, Janssen Pharmaceutica, Norepinephrine reuptake inhibitor, Serotonin reuptake inhibitor, Selective serotonin reuptake inhibitor, SPRAVATO®▼, Major Depressive Disorder, the Janssen Pharmaceutical Companies of Johnson & Johnson

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved SPRAVATO (esketamine) nasal spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (TRD).

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved SPRAVATO (esketamine) nasal spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (TRD).
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development of SPRAVATO.
  • FDA advisory committee recommends approval of SPRAVATOTM (esketamine) nasal spray CIII for adults with treatment-resistant depression.
  • Janssen Announces US FDA approval of SPRAVATOTM (esketamine) CIII nasal spray for adults with Treatment-Resistant Depression (TRD) who have cycled through multiple treatments without relief.

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023 Featuring Allergan, Eli Lilly and Co, GlaxoSmithKline, H. Lundbeck AS, Pfizer - ResearchAndMarkets.com

Retrieved on: 
금요일, 7월 26, 2019
Pharmaceutical, Health, Mental health, Branches of biology, Chemical compounds, Drugs, Selective serotonin reuptake inhibitors, RTT, Antidepressants, Serotonin reuptake inhibitor, Serotonin, Serotonin–norepinephrine reuptake inhibitor

Selective Serotonin Reuptake Inhibitors (SSRIs) are used to treat severe or persistent depression by elevating the extracellular levels of serotonin.

Key Points: 
  • Selective Serotonin Reuptake Inhibitors (SSRIs) are used to treat severe or persistent depression by elevating the extracellular levels of serotonin.
  • The selective serotonin reuptake inhibitors market analysis considers sales of the drugs for depression, anxiety and panic disorder, and other mental conditions.
  • This analysis also considers the sales of selective serotonin reuptake inhibitors in Asia, Europe, North America, and ROW.
  • With the presence of several major players, the global selective serotonin reuptake inhibitors market is fragmented.